Lovell Amy L, Makamo Nthongase, Veal Gareth J, Bernhardt Melanie B, Barr Ronald, Gala Rajul M, Gordon Erin, Ladas Elena J, Prasad Maya, Rogers Paul C, Schoeman Judy, Slone Jeremy S, Viani Karina, Tissing Wim J E, Huibers Minke H W
Department of Nutrition and Dietetics, The University of Auckland, Faculty of Medical and Health Sciences, Auckland, New Zealand.
Starship Blood and Cancer Centre, Starship Child Health, Te Whatu Ora, Te Toka Tumai, Auckland, New Zealand.
Br J Cancer. 2025 Jun 26. doi: 10.1038/s41416-025-03023-3.
Malnutrition (undernutrition or overweight/obesity) might significantly impact the pharmacokinetics and pharmacodynamics of antineoplastic drugs in children and adolescents (<21 years). A comprehensive systematic literature search was performed on MEDLINE (PubMed), EMBASE, Web of Science, Scopus, ProQuest, Cochrane Trials, and Cochrane Reviews. Databases were searched up to 30 September 2024. Of 4186 articles identified, 150 full texts were evaluated and 12 selected for inclusion. Eight additional articles were identified following a panel review and 6 included, resulting in a total of 18 articles for data extraction. Relevant pharmacokinetic parameters were described for mercaptopurine, vincristine, anthracyclines, methotrexate, busulfan, bevacizumab, and crizotinib. Due to the heterogeneity and limited number of studies per antineoplastic drug, formal statistical analysis or meta-analysis was not appropriate. Variations in the definition of nutritional status, dosing strategies, and type of pharmacokinetic analyses were observed; therefore, no dosing recommendations could be made. With the increasing childhood cancer burden in LMIC, high prevalence of undernutrition, and the global burden of childhood obesity, there is an urgent need for more research in this area. Prospective studies should incorporate uniform definitions and standardised pharmacological approaches to optimise treatment options for children with cancer globally. SYSTEMATIC LITERATURE REVIEW REGISTRATION: PROSPERO: (reference: CRD42023435261).
营养不良(营养不足或超重/肥胖)可能会显著影响儿童和青少年(<21岁)抗肿瘤药物的药代动力学和药效学。我们在MEDLINE(PubMed)、EMBASE、科学网、Scopus、ProQuest、Cochrane试验库和Cochrane系统评价数据库中进行了全面的系统文献检索。检索截至2024年9月30日的数据库。在识别出的4186篇文章中,评估了150篇全文,选取12篇纳入。小组评审后又识别出8篇文章,纳入6篇,最终共有18篇文章进行数据提取。描述了巯嘌呤、长春新碱、蒽环类药物、甲氨蝶呤、白消安、贝伐单抗和克唑替尼的相关药代动力学参数。由于每种抗肿瘤药物研究的异质性和数量有限,不适合进行正式的统计分析或荟萃分析。观察到营养状况定义、给药策略和药代动力学分析类型存在差异;因此,无法给出给药建议。鉴于低收入和中等收入国家儿童癌症负担不断增加、营养不足的高患病率以及全球儿童肥胖负担,该领域迫切需要更多研究。前瞻性研究应采用统一的定义和标准化的药理学方法,以优化全球癌症儿童的治疗方案。系统文献综述注册:PROSPERO:(参考文献:CRD42023435261)